These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8065709)

  • 1. Topical carbonic anhydrase inhibitors: potential adjuvants to glaucoma therapy in the future.
    Scott BT
    Optom Vis Sci; 1994 May; 71(5):332-8. PubMed ID: 8065709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor.
    Pfeiffer N
    Surv Ophthalmol; 1997; 42(2):137-51. PubMed ID: 9381367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy.
    Hiett JA; Dockter CA
    Optom Clin; 1992; 2(4):97-112. PubMed ID: 1286242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trusopt, a topical carbonic anhydrase inhibitor.
    Donohue EK; Wilensky JT
    J Glaucoma; 1996 Feb; 5(1):68-74. PubMed ID: 8795737
    [No Abstract]   [Full Text] [Related]  

  • 5. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
    Eichhorn M
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Topical carbonic anhydrase inhibitors in the treatment of glaucoma].
    Bayer A; Ferrari F; Maren TH; Erb C
    J Fr Ophtalmol; 1996; 19(5):357-62. PubMed ID: 8762903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase inhibitors as fourth drug in primary glaucomas: Is it worth it?
    Juncal VR; Abdo Jorge F; Paranhos A; Santos Prata T
    Can J Ophthalmol; 2015 Aug; 50(4):297-301. PubMed ID: 26257224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of dorzolamide.
    Martens-Lobenhoffer J; Banditt P
    Clin Pharmacokinet; 2002; 41(3):197-205. PubMed ID: 11929320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M; Cyrlin M; Lippa EA; Esposito D; Deasy D; Panebianco D; Fazio R; Yablonski M; Shields MB
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of glaucoma and the promising perspectives.
    Diestelhorst M
    Curr Opin Ophthalmol; 1996 Apr; 7(2):18-23. PubMed ID: 10163316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aqueous inflow inhibitors.
    Doyle JW; Smith MF
    Semin Ophthalmol; 1999 Sep; 14(3):159-63. PubMed ID: 10790580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the drug treatment of glaucoma.
    Hurvitz LM; Kaufman PL; Robin AL; Weinreb RN; Crawford K; Shaw B
    Drugs; 1991 Apr; 41(4):514-32. PubMed ID: 1711957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
    de Leval X; Ilies M; Casini A; Dogné JM; Scozzafava A; Masini E; Mincione F; Starnotti M; Supuran CT
    J Med Chem; 2004 May; 47(11):2796-804. PubMed ID: 15139757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness -- a cross-sectional study on 403 eyes].
    Viestenz A; Martus P; Schlötzer-Schrehardt U; Langenbucher A; Mardin CY
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):753-6. PubMed ID: 15459842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
    Ormrod D; McClellan K
    Drugs Aging; 2000 Dec; 17(6):477-96. PubMed ID: 11200308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
    Stoner A; Harris A; Oddone F; Belamkar A; Verticchio Vercellin AC; Shin J; Januleviciene I; Siesky B
    Br J Ophthalmol; 2022 Oct; 106(10):1332-1337. PubMed ID: 34433550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological profiles of the potent carbonic anhydrase inhibitor dorzolamide hydrochloride, a topical antiglaucoma agent].
    Kobayashi M; Naito K
    Nihon Yakurigaku Zasshi; 2000 Jun; 115(6):323-8. PubMed ID: 10948564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA; Wilde MI
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF; Ochsner KI
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trusopt--a new form of drug for treating glaucoma].
    Izdebska J
    Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.